TScan Therapeutics (TCRX) Cash from Investing Activities (2020 - 2025)
TScan Therapeutics (TCRX) has disclosed Cash from Investing Activities for 6 consecutive years, with $14.8 million as the latest value for Q4 2025.
- Quarterly Cash from Investing Activities fell 45.67% to $14.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $109.4 million through Dec 2025, up 307.88% year-over-year, with the annual reading at $109.4 million for FY2025, 307.88% up from the prior year.
- Cash from Investing Activities for Q4 2025 was $14.8 million at TScan Therapeutics, down from $32.6 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $48.4 million in Q2 2025, with the low at -$82.4 million in Q3 2024.
- Average Cash from Investing Activities over 5 years is -$908300.0, with a median of -$684500.0 recorded in 2022.
- The sharpest move saw Cash from Investing Activities tumbled 14384.43% in 2023, then skyrocketed 4415.39% in 2024.
- Over 5 years, Cash from Investing Activities stood at -$2.2 million in 2021, then surged by 37.72% to -$1.4 million in 2022, then surged by 238.93% to $1.9 million in 2023, then soared by 1326.71% to $27.3 million in 2024, then plummeted by 45.67% to $14.8 million in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods came in at $14.8 million, $32.6 million, and $48.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.